Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. - Wikidata - awgldk - TriplyDB

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

http://www.wikidata.org/entity/Q37627442

about

Intraocular Implants for the Treatment of Autoimmune Uveitis

P2860

Q26799168-06DA702D-85B8-4CAD-B6F0-2F1ADBF3372D

P2860

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

http://www.wikidata.org/entity/Q37627442

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@en

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@nl

type

label

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@en

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@nl

prefLabel

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@en

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@nl

P1433

Q37627442-A88D398B-4A28-4DDA-A505-F4FA643BA7FB

P1476

Q37627442-26D8B60D-18B8-4BB1-88A1-BAF3AC0E018A

P2093

Q37627442-04C3707D-4A86-457F-90D1-B5BFCC6E0FE8

Q37627442-2B93271E-876E-4E90-BED9-EEDA6856BB85

Q37627442-355814CC-1C2A-43B0-9819-741228CF6E0D

Q37627442-6E08F5C6-9A63-4185-9A14-B29F52B5C74C

Q37627442-74458597-70C9-4BC1-893A-2BE7EF49560C

Q37627442-8016C2D1-7C40-47EB-8655-B042B531BAE7

Q37627442-90A3018A-09CF-4080-BB62-1BC812A90817

Q37627442-AB189E4B-6D2B-4A0E-8514-CD28D02BF70D

Q37627442-B4659543-31A5-4CCD-8BDF-4299DF423436

P2860

Q37627442-0396169B-DD4B-4C71-9D7B-E9AFA38016D8

Q37627442-03D9A343-24EA-42BA-B4DE-B58347F86241

Q37627442-0458D794-4266-4B42-8AC6-D891D125136C

Q37627442-053AA10C-92B3-43F8-85B1-2B1A3112C98C

Q37627442-06804B6C-967C-48E0-AFEC-2D448A3611A8

Q37627442-08166B89-9F9E-4235-A1A3-F0D886990204

Q37627442-08BE8024-4F84-4903-9C63-78B6C95E7DAE

Q37627442-0C6C469F-76E4-439A-9BC8-04484C7DD64E

Q37627442-0C798A3F-0E8C-441B-A2D0-9349D2F6EC96

Q37627442-0CC696A6-D271-4CE5-A105-CA99EAF8C97C

P304

Q37627442-26434A1F-4544-4D27-8179-BF921BDC9937

P31

Q37627442-38F75B64-F834-4C31-B0C5-DF4DA20FEA2F

P356

Q37627442-1E4F0EC1-FA10-4266-A314-DABA331CE1FE

P433

Q37627442-04825536-07AD-45C1-AED1-201A294BC74B

P478

Q37627442-2BDCB6B5-4187-49B7-8670-EDCFF8E12BF6

P50

Q37627442-62DF48BA-8BA0-4114-A781-69921BEF25F0

P577

Q37627442-3A0E51B0-5230-4905-947D-C72D543905BA

P5875

Q37627442-F521F7CC-4C61-47B3-93F9-99DBAF8B834E

P698

Q37627442-AC6B996D-D72E-4D08-B525-51F4653EE567

P921

Q37627442-D242FE91-AF35-434A-BDD0-5E2485F29CF5

P932

Q37627442-5FAE1D12-1427-4D80-AA02-447B25C5C876

P356

P1433

Journal of personalized medicine

P1476

Personalized Medicine in Ophth ...... eutic and Dosage Optimization.

@en

P2093

Brian L Taylor

http://www.w3.org/2001/XMLSchema#string

Chi-Chun Lai

http://www.w3.org/2001/XMLSchema#string

Ching-Yu Cheng

http://www.w3.org/2001/XMLSchema#string

Frank S Ong

http://www.w3.org/2001/XMLSchema#string

Jane Z Kuo

http://www.w3.org/2001/XMLSchema#string

Tien Y Wong

http://www.w3.org/2001/XMLSchema#string

Wayne W Grody

http://www.w3.org/2001/XMLSchema#string

Wei-Chi Wu

http://www.w3.org/2001/XMLSchema#string

Wendell-Lamar B Blackwell

http://www.w3.org/2001/XMLSchema#string

P2860

Potential etiologic and functional implications of genome-wide association loci for human diseases and traits

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Complement factor H polymorphism in age-related macular degeneration

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

HTRA1 promoter polymorphism in wet age-related macular degeneration

P304

40-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JPM3010040

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Jerome I Rotter

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260761762

http://www.w3.org/2001/XMLSchema#string

P698

24624293

http://www.w3.org/2001/XMLSchema#string

P921

P932

3947950

http://www.w3.org/2001/XMLSchema#string